Related Experiment Video
Updated: Jan 27, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids
Clémence Dubois1,2, Pierre Daumar3, Corinne Aubel4
1Université Clermont Auvergne, Institut Universitaire de Technologie, INSERM, U1240, Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont Ferrand, France. clemence.dubois@uca.fr.
Abstract:
Triple-negative breast cancers are particularly aggressive. In vitro cultures are one of the major pathways for developing anticancer strategies. The effectiveness and reproducibility of the drug screenings depend largely on the homogeneity of culture media. In order to optimize the predictive responses of triple-negative breast cancer 3D cell culture models, these works were focused on the development of SUM1315 and MDA-MB-231 cell lines in OptiPASS medium, a new serum-free formulation (BIOPASS). In monolayer cell culture, OptiPASS medium was more suitable for MDA-MB-231 than SUM1315 cell line but maintained cell phenotype and allowed sufficient proliferation. For spheroids produced in OptiPASS, the size monitoring showed a 1.3 and 1.5-fold increase for MDA-MB-231 and SUM1315 cell lines, respectively and viability/mortality profiles were maintained. Spheroids drug sensitivity thresholds were also improved allowing quicker high throughput drug screenings. These results showed the suitability of OptiPASS for 2D and 3D cell cultures of these two triple-negative breast cancer cell lines, with reproducibility of spheroid formation superior to 98%. This opens the way to the common use of this synthetic medium in future preclinical breast cancer research studies.
Insights
OptiPASS, a serum-free medium, enhances triple-negative breast cancer cell cultures for improved drug screening. This new formulation supports both 2D and 3D cultures, increasing reproducibility and predictive responses in preclinical research.
Area of Science:
- Oncology
- Cell Biology
- Biotechnology
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype requiring effective therapeutic strategies.
- In vitro cell cultures are crucial for developing and screening anticancer drugs.
- Culture media homogeneity is vital for reproducible drug screening results.
Purpose of the Study:
- To develop and evaluate OptiPASS, a novel serum-free medium, for optimizing triple-negative breast cancer (TNBC) 3D cell culture models.
- To assess the suitability of OptiPASS for SUM1315 and MDA-MB-231 TNBC cell lines in both 2D and 3D cultures.
- To improve the predictive responses and efficiency of drug screenings using TNBC cell models.
Main Methods:
- Cultured SUM1315 and MDA-MB-231 TNBC cell lines in OptiPASS medium.
- Evaluated cell proliferation, phenotype, and viability in monolayer (2D) and spheroid (3D) cultures.
- Assessed spheroid size, viability/mortality profiles, and drug sensitivity thresholds.
- Determined the reproducibility of spheroid formation.
Main Results:
- OptiPASS supported proliferation and maintained cell phenotype in monolayer cultures for both cell lines, with better suitability for MDA-MB-231.
- Spheroids formed in OptiPASS showed increased size (1.3-1.5 fold) and maintained viability/mortality profiles.
- Drug sensitivity thresholds were improved, enabling faster high-throughput drug screenings.
- Spheroid formation reproducibility exceeded 98% for both cell lines in OptiPASS.
Conclusions:
- OptiPASS is suitable for both 2D and 3D cell cultures of SUM1315 and MDA-MB-231 TNBC cell lines.
- The serum-free medium enhances spheroid formation reproducibility and drug screening efficiency.
- OptiPASS shows promise for widespread use in preclinical breast cancer research.
Related Concept Videos
01:16Cell Lines
02:36Cells Coordinate Growth and Proliferation
02:40The Eukaryotic Promoter Region
02:23Abnormal Proliferation
02:27Predicting Molecular Geometry
01:29Self-Efficacy